15th Mar 2021 10:43
SkinBioTherapeutics PLC - AIM-listed life science company - Reports pretax loss of GBP628,241 for half-year to December 31, narrowing from GBP889,002 a year ago. This is as research & development expenses more than halve to GBP205,027 from GBP455,052.
Company says it made "strong progress" over the first half.
"We acted decisively and swiftly in adapting our AxisBiotix-Ps food supplement consumer study into a format that allowed for remote participation, which we successfully launched post-period end. Our SkinBiotix cosmetic programme is progressing on schedule, with Croda/Sederma making excellent strides on both the manufacturing and commercial positioning sides. We anticipate seeing significant progress in both areas of work during 2021," says Chief Executive Stuart Ashman.
Current stock price: 48.50 pence
Year-to-date change: doubled from 23.5p at end of 2020
By Lucy Heming;Â [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Skinbiotherap.